Skip to main content
. 2019 Oct 25;21(6):108. doi: 10.1208/s12248-019-0378-y

Fig. 3.

Fig. 3

Point Estimates and 90% confidence intervals for the bioavailability of upadacitinib following administration of single doses of upadacitinib 30 mg extended-release tablets with different release rates relative to single 24 mg dose of the upadacitinib immediate-release capsules